Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (NASDAQ: PTCT) and Community Health (NYSE: CYH)

By Jason Carr

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PTC Therapeutics (NASDAQ: PTCT) and Community Health (NYSE: CYH).

PTC Therapeutics (NASDAQ: PTCT)

In a report released today, Joel Beatty from Citigroup upgraded PTC Therapeutics (NASDAQ: PTCT) to Buy. The company’s shares opened today at $10.63.

According to TipRanks.com, Beatty is ranked 0 out of 5 stars with an average return of -17.5% and a 27.8% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Dimension Therapeutics Inc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Currently, the analyst consensus on PTC Therapeutics is Moderate Buy and the average price target is $17.50, representing a 64.6% upside.

In a report issued on November 2, Barclays also reiterated a Buy rating on the stock with a $20 price target.
Community Health (NYSE: CYH)

Credit Suisse analyst Scott Fidel downgraded Community Health (NYSE: CYH) to Sell today. The company’s shares opened today at $4.73, close to its 52-week low of $0.

According to TipRanks.com, Fidel is a 5-star analyst with an average return of 8.6% and a 57.0% success rate. Fidel covers the Healthcare sector, focusing on stocks such as WellCare Health Plans, Universal American, and Molina Healthcare.

Currently, the analyst consensus on Community Health is Hold and the average price target is $9.67, representing a 104.4% upside.

In a report issued on October 27, Mizuho Securities also downgraded the stock to Sell with a $3 price target.